Industry: Pharmaceuticals, Biotechnology
Maxygen Inc., headquartered in Redwood City, California, is committed to the discovery, development and commercialization of improved, next-generation protein pharmaceuticals for the treatment of human disease and serious medical conditions. To date, Maxygen has raised more than $80 million in non-dilutive funds from the sale of Maxygen non-core assets, including proceeds from the sale of its agricultural subsidiary, Verdia, Inc., to Pioneer Hi-Bred International (DuPont), and proceeds from its equity interest in Avidia, Inc. As of September 30, 2006, Maxygen had cash and cash equivalents of approximately $170 million. Maxygen last raised money from investors in a secondary public offering in March ( www.maxygen.com )
Maxygen , Inc.
301 Galveston Drive
Redwood City, California 94063
USA
Tel: (650) 298-5300
Fax: (650) 364-2715